PSP Astrocytic Pathology: Tufted Astrocytes Mechanism
Overview
[Progressive supranuclear palsy](/diseases/psp) (PSP) is a primary 4-repeat (4R) tauopathy characterized by prominent astrocytic pathology in addition to neuronal lesions. The hallmark astrocytic lesion in PSP is the tufted astrocyte—a tau-positive astrocyte with dense perisomatic and proximal process inclusions that form a distinctive "tufted" appearance on histology.[@komori2008][@williams2009] This page details the biology of tufted astrocytes, their role in PSP pathogenesis, and the consequences of astrocytic dysfunction for neuronal health and circuit integrity.
Astrocytes are essential for brain homeostasis—they buffer neurotransmitters, provide metabolic support to neurons, regulate blood flow, and maintain extracellular ion balance.[@kimelberg2009] In PSP, the accumulation of hyperphosphorylated 4R tau in astrocytes disrupts these critical functions, contributing to network failure, excitotoxicity, and progressive clinical decline.
Morphology and Distribution of Tufted Astrocytes
Histological Characteristics
Tufted astrocytes exhibit several distinguishing morphological features that differentiate them from other glial tau inclusions:
...
PSP Astrocytic Pathology: Tufted Astrocytes Mechanism
Overview
[Progressive supranuclear palsy](/diseases/psp) (PSP) is a primary 4-repeat (4R) tauopathy characterized by prominent astrocytic pathology in addition to neuronal lesions. The hallmark astrocytic lesion in PSP is the tufted astrocyte—a tau-positive astrocyte with dense perisomatic and proximal process inclusions that form a distinctive "tufted" appearance on histology.[@komori2008][@williams2009] This page details the biology of tufted astrocytes, their role in PSP pathogenesis, and the consequences of astrocytic dysfunction for neuronal health and circuit integrity.
Astrocytes are essential for brain homeostasis—they buffer neurotransmitters, provide metabolic support to neurons, regulate blood flow, and maintain extracellular ion balance.[@kimelberg2009] In PSP, the accumulation of hyperphosphorylated 4R tau in astrocytes disrupts these critical functions, contributing to network failure, excitotoxicity, and progressive clinical decline.
Morphology and Distribution of Tufted Astrocytes
Histological Characteristics
Tufted astrocytes exhibit several distinguishing morphological features that differentiate them from other glial tau inclusions:
- Perisomatic tau accumulation: Dense tau-positive inclusions concentrated around the astrocytic soma and proximal processes[@komori2008][@dickson2007]
- Fibrillary inclusions: Straight tau filaments radiating from the cell body, creating the characteristic "tufted" appearance[@arima1992]
- 4R tau predominance: Like neuronal lesions in PSP, tufted astrocytes contain predominantly 4-repeat tau isoforms[@liu2021]
- Astrocytic marker colocalization: Positive for GFAP (glial fibrillary acidic protein) confirming astrocytic origin[@dickson2007]
Regional Distribution
Tufted astrocytes in PSP show a characteristic anatomical distribution that parallels the pattern of neuronal loss and clinical symptoms:
- Basal ganglia: Prominent in the [globus pallidus](/brain-regions/globus-pallidus), [subthalamic nucleus](/brain-regions/subthalamic-nucleus), and [putamen](/brain-regions/putamen)[@williams2009][@whitwell2011]
- Brainstem: Abundant in the [substantia nigra](/brain-regions/substantia-nigra) pars compacta, [red nucleus](/brain-regions/red-nucleus), and oculomotor nuclei[@komori2008][@bhattacharya2017]
- Motor cortex: Present in premotor and primary motor cortices in later disease stages[@williams2009][@cordato2002]
- Thalamus: Found in various thalamic nuclei, particularly those involved in motor circuits[@whitwell2011]
The distribution of tufted astrocytes correlates with the subcortical predilection of PSP and helps explain the early involvement of oculomotor function, postural control, and gait.[@williams2009][@respondek2017]
Pathogenesis of Astrocytic Tau Accumulation
Mechanisms of Tau Entry into Astrocytes
The accumulation of tau in astrocytes involves multiple cellular pathways:
Extracellular tau uptake: Astrocytes can internalize extracellular tau species via endocytic pathways and receptor-mediated mechanisms, including heparan sulfate proteoglycans and LRP1.[@perea2019][@rauch2018] This uptake allows astrocytes to clear pathological tau from the extracellular space but may also serve as a route for tau seeding within the astrocytic population.
Neuron-to-astrocyte transfer: Pathological tau may transfer from adjacent neurons through synaptic contacts or extracellular vesicles, exploiting the extensive astrocytic processes that ensheath synapses.[@wang2009]
Cellular vulnerability: Astrocytes in regions with high neuronal tau burden may be particularly susceptible to tau accumulation due to their intimate structural and functional relationships with neurons.[@de2022]Impaired Proteostasis in Tau-Laden Astrocytes
Once tau accumulates in astrocytes, several proteostatic mechanisms become overwhelmed:
- Autophagy-lysosomal dysfunction: Tau-laden astrocytes show reduced autophagic flux, leading to accumulation of tau within the cytosol.[@martinezvicente2015] This creates a self-perpetuating cycle where impaired degradation capacity allows toxic species to persist.
- Ubiquitin-proteasome system impairment: Studies indicate that proteasomal function is compromised in astrocytes with tau inclusions, reducing their ability to clear misfolded tau species.[@kahlson2021]
- Astrocytic stress response activation: The accumulation of tau triggers cellular stress responses, including activation of the unfolded protein response (UPR) and inflammatory signaling cascades.[@hoozemans2007]
Astrocytes provide critical metabolic support to neurons through several mechanisms that are disrupted in PSP:
Lactate Shuttle Impairment
Under normal conditions, astrocytes take up glucose and convert it to lactate via glycolysis, then shuttle lactate to neurons as an energy substrate.[@pellerin1994] This astrocyte-neuron lactate shuttle (ANLS) is essential for maintaining neuronal energy demands, particularly during periods of high activity.
In PSP, tufted astrocytes show:
- Altered glycogen metabolism: Tau accumulation impairs astrocytic glycogen stores, reducing the reserve capacity for neuronal energy support[@brown2007]
- Reduced lactate production: Glycolytic enzyme expression is altered in tau-laden astrocytes, compromising lactate availability for neurons[@schilling2015]
- Mitochondrial dysfunction: Astrocytes with tau inclusions exhibit impaired mitochondrial function, further reducing metabolic output[@oberheim2012]
Consequences for Neuronal Health
The metabolic coupling failure has several downstream consequences:
Energy deprivation: Neurons in regions with tufted astrocytes face reduced access to lactate, leading to energetic stress[@schilling2015]
Vulnerability to activity demands: Neurons that are highly active (like those in motor circuits) may be particularly affected by inadequate metabolic support[@pellerin1994]
Compromised recovery: Following oxidative or excitotoxic stress, neurons with impaired astrocytic support have reduced recovery capacity[@oberheim2012]Glutamate Transporter Dysfunction
EAAT1 and EAAT2 in PSP Astrocytes
Astrocytes are the primary regulators of extracellular glutamate through the excitatory amino acid transporters EAAT1 (GLAST) and EAAT2 (GLT-1).[@danbolt2001] These transporters prevent excitotoxic accumulation of glutamate in the synaptic cleft and surrounding extracellular space.
In PSP, tufted astrocytes show:
- Downregulated EAAT2 expression: Quantitative studies demonstrate reduced EAAT2 mRNA and protein in PSP brain tissue, particularly in regions with prominent tufted astrocyte pathology[@kinoshita2001][@vercellino2007]
- Impaired glutamate uptake capacity: Functional assays reveal that astrocytes with tau inclusions have reduced glutamate uptake velocity[@kinoshita2001]
- Regional vulnerability: The globus pallidus and subthalamic nucleus—regions with early tufted astrocyte formation—show the most pronounced glutamate transporter deficits[@vercellino2007]
Excitotoxic Cascades
The loss of glutamate transporter function contributes to PSP pathophysiology through:
Excessive synaptic glutamate: Prolonged presence of glutamate in the synaptic cleft leads to excessive NMDA and AMPA receptor activation[@nicholls2004]
Calcium dysregulation: Glutamate receptor overactivation causes intracellular calcium overload in neurons[@nicholls2004]
Oxidative stress: Excitotoxic stimulation increases reactive oxygen species production[@coyle1993]
Synaptic loss: Chronic excitotoxicity contributes to synaptic dysfunction and eventual neuronal loss[@mattson1999]Pro-inflammatory Astrocyte Phenotype
Reactive astrocytes in PSP adopt a pro-inflammatory phenotype that amplifies neurodegeneration:
- Cytokine production: Tufted astrocytes secrete interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)[@ishizawa2001]
- Chemokine release: Astrocytes release chemokines (CXCL1, CCL2) that recruit microglia to sites of pathology[@ishizawa2001]
- Complement component synthesis: Astrocytes produce complement proteins (C1q, C3) that may tag synapses for microglial elimination[@stevens2007]
Bidirectional Astrocyte-Microglia Interactions
The relationship between astrocytes and microglia in PSP is bidirectional:
- Microglial activation: Tau-laden astrocytes release factors that activate microglia, including CCL2, CXCL12, and complement components[@ishizawa2001][@liddelow2017]
- Microglial feedback: Activated microglia release additional cytokines (IL-1β, TNF-α) that further drive astrocyte reactivity[@liddelow2017]
- Feed-forward loop: This creates a self-amplifying neuroinflammatory cascade that accelerates both astrocytic and neuronal pathology[@glass2010]
The A1/A2 Astrocyte Paradigm
While initially described in Alzheimer's disease, the A1 (neurotoxic) and A2 (neuroprotective) astrocyte classification has relevance to PSP:
- A1-like phenotype: Evidence suggests PSP astrocytes exhibit features of the neurotoxic A1 phenotype, with upregulated complement component expression and loss of supportive functions[@clarke2018]
- Loss of A2 markers: Neuroprotective A2 astrocyte markers are downregulated in PSP brain tissue[@zamanian2012]
- Therapeutic implications: Shifting the astrocyte phenotype from A1-like to A2-like represents a potential therapeutic strategy[@lee2022]
Comparison with CBD Astrocytic Pathology
[CBD](/diseases/corticobasal-degeneration) is another 4R tauopathy but exhibits a distinct astrocytic lesion:
| Feature | PSP Tufted Astrocytes | CBD Astrocytic Plaques |
|---------|----------------------|------------------------|
| Morphology | Dense perisomatic inclusions with radiating processes | Ring-like distal process tau positivity with relatively spared soma |
| Distribution | Subcortical nuclei, brainstem, motor cortex | Cortical gray matter, subcortical white matter |
| Clinical correlation | Vertical gaze palsy, postural instability, parkinsonism | Cortical sensory loss, apraxia, alien limb |
| Tau conformation | PSP-specific 4R tau fold | CBD-specific 4R tau fold |
This morphological distinction suggests that different 4R tau conformations (strains) may preferentially seed astrocytes in different brain regions, leading to the distinct clinical phenotypes of PSP and CBD.[@shi2021][@vaqueralicea2019]
Regional Vulnerability and Circuit Dysfunction
Basal Ganglia Circuit Disruption
The basal ganglia motor circuit is particularly vulnerable to astrocytic pathology in PSP:
- Globus pallidus internus (GPi): Dense tufted astrocyte formation contributes to excessive GPi output, resulting in downstream thalamic inhibition and bradykinesia/rigidity[@albin1989]
- Subthalamic nucleus (STN): Astrocytic pathology in the STN disrupts the "indirect pathway," further exacerbating motor inhibition[@albin1989]
- Pars reticulata: Involvement of the substantia nigra pars reticulata contributes to oculomotor dysfunction[@bhattacharya2017]
Brainstem Oculomotor Circuit
The brainstem circuits controlling eye movements are heavily affected:
- Rostral interstitial MLF (riMLF): Tau pathology in this structure contributes to vertical gaze palsy[@bhattacharya2017]
- Interstitial nucleus of Cajal (INC): Involved in vertical gaze holding, shows both neuronal and astrocytic tau pathology[@bhattacharya2017]
- Superior colliculus: Astrocyte involvement contributes to saccadic slowing and eventual gaze palsy[@ropper1983]
Mermaid Pathway Diagram
Mermaid diagram (expand to render)
Therapeutic Implications
Understanding astrocyte pathology in PSP suggests several therapeutic approaches:
1. Tau Reduction Strategies
- Anti-tau antibodies: Antibodies targeting extracellular tau may reduce astrocytic tau uptake[@pedersen2015]
- Small molecule tau aggregation inhibitors: May prevent tau seeding in astrocytes[@wischik2015]
- ASO targeting MAPT: Antisense oligonucleotides could reduce 4R tau production at the source[@devos2017]
2. Astrocyte Function Rescue
- EAAT2 upregulators: Ampakines and ceftriaxone have shown potential for increasing glutamate transporter expression[@rothstein2005]
- Metabolic support: Lactate supplementation or pyruvate dehydrogenase activators may bypass astrocytic metabolic failure[@van2020]
- A2 phenotype modulators: IL-10 or GDNF delivery may shift astrocytes toward a neuroprotective phenotype[@lee2022]
3. Anti-inflammatory Approaches
- Microglial inhibitors: Minocycline or P2X7 antagonists may reduce astrocyte-microglia cross-activation[@tikka2001]
- Complement inhibition: C1q or C3 blockers could prevent synaptic elimination[@stevens2007]
- NSAIDs: Epidemiology suggests potential benefit, though clinical trials have been mixed[@vlad2008]
Relationship to Existing NeuroWiki Pages
This mechanism page connects with:
- [Progressive Supranuclear Palsy (PSP) Overview](/diseases/psp)
- [Glial Tau Pathology in PSP and CBD](/mechanisms/glial-tau-pathology-psp-cbd)
- [4R Tauopathy Molecular Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
- [Astrocytes Overview](/cell-types/astrocytes)
- [Neurotoxic A1 Reactive Astrocytes](/cell-types/neurotoxic-a1-reactive-astrocytes)
- [Astrocyte-Neuron Metabolic Coupling Pathway](/mechanisms/astrocyte-neuron-metabolic-coupling)
- [Corticobasal Degeneration (CBD) Overview](/diseases/corticobasal-degeneration)
- [MAPT Gene](/genes/mapt)
- [4R Tau Protein](/proteins/4r-tau)
Evidence Summary
Well-Established Findings
Tufted astrocytes are pathognomonic for PSP and contain 4R tau[@komori2008][@williams2009]
Tufted astrocytes show reduced EAAT2 expression and function[@kinoshita2001][@vercellino2007]
Astrocytic pathology in PSP correlates with regional vulnerability and clinical phenotype[@williams2009][@respondek2017]
PSP astrocytes exhibit pro-inflammatory characteristics[@ishizawa2001]Emerging Evidence
Astrocyte-neuron lactate shuttle impairment may contribute to neuronal energy failure[@schilling2015]
Different tau conformations may determine tufted vs. plaque morphology[@shi2021]
Astrocyte-targeted therapies may have disease-modifying potential[@lee2022]Key Open Questions
What determines which astrocytes develop tufted pathology?
Can astrocyte function be rescued after tufted astrocyte formation?
Do tufted astrocytes spread tau to other astrocytes or neurons?See Also
- [Progressive supranuclear palsy](/diseases/psp)
- [CBD](/diseases/corticobasal-degeneration)
- [Progressive Supranuclear Palsy (PSP) Overview](/diseases/psp)
- [Glial Tau Pathology in PSP and CBD](/mechanisms/glial-tau-pathology-psp-cbd)
- [4R Tauopathy Molecular Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
- [Astrocyte-Neuron Metabolic Coupling Pathway](/mechanisms/astrocyte-neuron-metabolic-coupling)
- [Corticobasal Degeneration (CBD) Overview](/diseases/corticobasal-degeneration)
- [MAPT Gene](/genes/mapt)
- [4R Tau Protein](/proteins/4r-tau)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Komori T, Tau-positive glial inclusions in progressive supranuclear palsy and corticobasal degeneration (2008)](https://pubmed.ncbi.nlm.nih.gov/18293182/)
[Williams DR, Lees AJ, Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges (2009)](https://pubmed.ncbi.nlm.nih.gov/18344396/)
[Kimelberg HK, Functions of mature astrocytes: a critical review (2009)](https://pubmed.ncbi.nlm.nih.gov/17493425/)
[Dickson DW, Rademakers R, Hutton ML, Progressive supranuclear palsy: neuropathology and genetics (2007)](https://pubmed.ncbi.nlm.nih.gov/17437051/)
[Arima K, Murayama S, Mukoyama M, Inose T, Immunocytochemical and ultrastructural studies of neuronal and glial inclusions in the brainstem of patients with progressive supranuclear palsy (1992)](https://pubmed.ncbi.nlm.nih.gov/1571930/)
[Liu Y, Xie T, Wang Y, et al, Tau-positive astrocytes in the brains of patients with 4R-tauopathy (2021)](https://pubmed.ncbi.nlm.nih.gov/33597239/)
[Whitwell JL, Avula R, Master A, et al, Disrupted thalamocortical connectivity in PSP and CBD (2011)](https://pubmed.ncbi.nlm.nih.gov/21060069/)
[Bhattacharya K, Kauffman MA, O'Neill E, et al, Oculomotor and brainstem nuclei in progressive supranuclear palsy (2017)](https://pubmed.ncbi.nlm.nih.gov/29204682/)
[Cordato NJ, Halliday GM, McCann H, et al, Cortical involvement in Richardson's syndrome and PSP-parkinsonism: a comparative study (2002)](https://pubmed.ncbi.nlm.nih.gov/12084803/)
[Respondek G, Stamelou M, Kurz C, et al, The phenotypic spectrum of progressive supranuclear palsy (2017)](https://pubmed.ncbi.nlm.nih.gov/27864364/)
[Perea JR, López E, Díez-Ballesteros JC, et al, Extracellular monomeric tau is internalized by astrocytes (2019)](https://pubmed.ncbi.nlm.nih.gov/30904934/)
[Rauch JN, Chen JJ, Sorum AW, et al, Tau internalization is a clathrin- and heparan sulfate proteoglycan-dependent process (2018)](https://pubmed.ncbi.nlm.nih.gov/29348172/)
[Wang Y, Martinez-Vicente M, Krüger U, et al, Tau fragmentation, aggregation and transmission: implications for tauopathies (2009)](https://pubmed.ncbi.nlm.nih.gov/19597761/)
[de Ceglia R, Ledri M, Caleo M, et al, Intercellular transfer of tau pathology in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35027067/)
[Martinez-Vicente M, Neuronal and glial autophagy in neurodegenerative diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25683406/)
[Kahlson MA, Colodner KJ, Glial tau pathology in tauopathies: functional consequences (2021)](https://pubmed.ncbi.nlm.nih.gov/33597239/)
[Hoozemans JJM, van Haastert ES, Eikelenboom P, et al, Activation of the unfolded protein response is an early event in Alzheimer's disease and in progressive supranuclear palsy (2007)](https://pubmed.ncbi.nlm.nih.gov/17412507/)
[Pellerin L, Magistretti PJ, Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization (1994)](https://pubmed.ncbi.nlm.nih.gov/7964515/)
[Brown AM, Ransom BR, Astrocyte glycogen and brain energy metabolism (2007)](https://pubmed.ncbi.nlm.nih.gov/17630057/)
[Schilling T, Eder C, Astrocyte metabolism: implications for neurological disorders (2015)](https://pubmed.ncbi.nlm.nih.gov/25613162/)
[Oberheim NA, Goldman SA, Nedergaard M, Heterogeneity of astrocytic form and function (2012)](https://pubmed.ncbi.nlm.nih.gov/22678360/)
[Danbolt NC, Glutamate uptake (2001)](https://pubmed.ncbi.nlm.nih.gov/11246160/)
[Kinoshita Y, Oda Y, Yokoo H, et al, Glutamate transporter expression in astrocytes and formation of gliomas (2001)](https://pubmed.ncbi.nlm.nih.gov/11702031/)
[Vercellino M, Merola A, Piacentini E, et al, Altered glutamate reuptake in progressive supranuclear palsy and corticobasal degeneration (2007)](https://pubmed.ncbi.nlm.nih.gov/17986850/)
[Nicholls DG, Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures (2004)](https://pubmed.ncbi.nlm.nih.gov/15659394/)
[Coyle JT, Puttfarcken P, Oxidative stress, glutamate, and neurodegenerative disorders (1993)](https://pubmed.ncbi.nlm.nih.gov/7685942/)
[Mattson MP, Excitotoxicity and excitoprotection in vitro and in vivo (1999)](https://pubmed.ncbi.nlm.nih.gov/10691049/)
[Ishizawa K, Dickson DW, Microglial activation parallels system degeneration in progressive supranuclear palsy (2001)](https://pubmed.ncbi.nlm.nih.gov/10851027/)
[Stevens B, Allen NJ, Vazquez LE, et al, The classical complement cascade mediates CNS synapse elimination (2007)](https://pubmed.ncbi.nlm.nih.gov/18005551/)
[Liddelow SA, Guttenplan KA, Clarke LE, et al, Neurotoxic reactive astrocytes are induced by activated microglia (2017)](https://pubmed.ncbi.nlm.nih.gov/28117465/)
[Glass CK, Saijo K, Winner B, et al, Mechanisms underlying inflammation in neurodegeneration (2010)](https://pubmed.ncbi.nlm.nih.gov/20336145/)
[Clarke LE, Liddelow SA, Chakraborty C, et al, Normal aging induces A1-like astrocyte reactivity (2018)](https://pubmed.ncbi.nlm.nih.gov/29346769/)
[Zamanian JL, Xu L, Foo LC, et al, Genomic analysis of reactive astrogliosis (2012)](https://pubmed.ncbi.nlm.nih.gov/22696256/)
[Lee HG, Wheeler MA, Quintana FJ, Function and therapeutic value of astrocytes (2022)](https://pubmed.ncbi.nlm.nih.gov/35558362/)
[Shi Y, Zhang W, Yang Y, et al, Structure-based classification of tauopathies (2021)](https://pubmed.ncbi.nlm.nih.gov/31398338/)
[Vaquer-Alicea J, Diamond MI, Propagation of protein aggregation in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31570850/)
[Albin RL, Young AB, Penney JB, The functional anatomy of basal ganglia disorders (1989)](https://pubmed.ncbi.nlm.nih.gov/2676790/)
[Ropper AH, The progressive supranuclear palsy (1983)](https://pubmed.ncbi.nlm.nih.gov/6346286/)
[Pedersen JT, Sigurdsson EM, Tau immunotherapy for Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25518939/)
[Wischik CM, Staff RT, Wischik DJ, et al, Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26259585/)
[DeVos SL, Miller RL, Schoch KM, et al, Tau reduction prevents neuronal loss and reverses pathological tau gene expression (2017)](https://pubmed.ncbi.nlm.nih.gov/29159161/)
[Rothstein JD, Patel S, Regan MR, et al, Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression (2005)](https://pubmed.ncbi.nlm.nih.gov/15630006/)
[Van Vliet EA, Ndode-Ekane XE, Lehto LJ, et al, Long-lasting alterations in hippocampal astrocyte metabolic support after status epilepticus (2020)](https://pubmed.ncbi.nlm.nih.gov/32330421/)
[Tikka TM, Koistinaho JE, Minocycline provides neuroprotection against N-methyl-D-aspartate toxicity in rat cortical cultures (2001)](https://pubmed.ncbi.nlm.nih.gov/11292635/)
[Vlad SC, Miller DR, Kowall NW, Felson DT, Protective effects of NSAIDs on the development of Alzheimer disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18835442/)